Logo Logo
Switch Language to German

Kolben, Thomas; Augustine, D.; Armbrust, R.; Kolben, T. M.; Degenhardt, T.; Burgmann, M.; Goess, C.; Ditsch, N.; Kates, R.; Harbeck, N. and Wuerstlein, R. (2016): Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. In: Breast Cancer Research and Treatment, Vol. 155, No. 1: pp. 109-115

Full text not available from 'Open Access LMU'.


The purpose of this study was to evaluate the influence of guideline-based prospective use of uPA/PAI-1 on clinical outcome in an intermediate-risk cohort of breast cancer patients. We analyzed 381 consecutive primary breast cancer patients (2003-2011) at the breast center Ostbayern meeting the following criteria: MO/NO/estrogen receptor (ER)+/G2. Clinical pathological data, uPA/PAI-1, and follow-up data were collected. Decisions for adjuvant chemotherapy were made upon consideration of prospectively measured uPA/PAI-1. Observed disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan Meier estimates. Using guideline -based analysis of uPA/PAI-1, treatment with adjuvant chemotherapy was avoided in 86.5 % of patients with low uPA/PAI-1, i.e., 38.8 % of the total patient collective. Median follow-up was 52.5 months. Five-year relapse-free survival in intermediate-risk patients (NO, G2) without chemotherapy was 99 %. Five-year overall survival including all causes of death was 95 %. By using uPA/PAI-1, adjuvant chemotherapy can be avoided in a major part of patients with intermediate-risk breast cancer. Nevertheless, DFS and OS of these patients at 5 years remain excellent. The potential, but hardly measurable, benefit of adjuvant chemotherapy has to be set in contrast with its associated side effects and increased morbidity. Patients with high uPA/PAI-1 show benefit from chemotherapy. In this subgroup, a very good OS was observed as well. These findings strongly support the use of uPA/PAI-1 together with clinic-pathological parameters as an evidence -based, clinically relevant and inexpensive decision tool in the routine of a breast center.

Actions (login required)

View Item View Item